Pharmaplast SAE

Form 483 issued November 10, 2022 · Alexandria, Egypt

Inspection
Nov 6 – Nov 10, 2022
Investigator
Michael A. Charles
Observations
7
Pages
3
FEI number
3003767891

In short: On November 10, 2022, FDA issued a Form 483 with 7 observations to Pharmaplast SAE in Alexandria, Egypt (FEI 3003767891) after an inspection that ran Nov 6 – Nov 10, 2022. The investigator was Michael A. Charles. Most observations concern facilities & equipment and production; the most-cited regulation is 21 CFR 211.188 (batch production and control records).

At a glance

Observations span 4 systems, led by facilities & equipment.

Facilities & equipment2
Production2
Laboratory controls1
Materials1
Other1

What FDA observed

Preview: the opening words of each observation
  1. 01

    Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory…

  2. 02

    Specific identification tests are not conducted on components that have been accepted based on the supplier's…

  3. 03

    There is a failure to supply potable water…

  4. 04

    The batch production and control records are deficient in that they do not include documentation of…

3 more observations

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Pharmaplast SAE?

FDA listed 7 observations on this Form 483, mostly about facilities & equipment, production and laboratory controls. The most-cited regulation is 21 CFR 211.188 (batch production and control records). The opening words of each observation are shown on this page.

Who inspected Pharmaplast SAE?

Michael A. Charles is named on this Form 483, for the inspection of Nov 6 – Nov 10, 2022. Each investigator has a profile showing what they cite most.

When was Pharmaplast SAE inspected by FDA?

The inspection ran Nov 6 – Nov 10, 2022, and the Form 483 is dated November 10, 2022.

How do I get the full Form 483 for Pharmaplast SAE?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free